Amplitude Unveils New Experimentation Application for Digital Optimization
10.6.2021 12:54:00 EEST | Business Wire | Press release
Amplitude’s Virtual Digital Disruptors Summit — Amplitude, the Digital Optimization System, today introduced Amplitude Experiment, the industry’s first experimentation solution powered by customer behavior and product analytics. Amplitude Experiment provides organizations an end-to-end experimentation and delivery workflow that integrates customer data into every step from generating a hypothesis to targeting users to measuring results. Organizations are empowered to run higher impact A/B tests and remotely configure experiences for key segments without incremental engineering work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005437/en/
New Amplitude Experiment product leverages customer behavior and product analytics to eliminate the barriers to scaling A/B testing programs (Graphic: Business Wire)
“Every company needs to be digital first, but too many are guessing what they should build next and wasting time on experiments that are doomed to fail,” said Justin Bauer, SVP Product, Amplitude. “Since Experiment is powered by customer behavior, businesses can free themselves from low-impact activities and get the invaluable insight that can accelerate and truly scale how they design and deliver digital products and experiences. This is an entirely new chapter for A/B testing that enables any company - whether they’re digital native or embarking on their digital transformation journey - to make bigger and smarter bets that drive stronger business results.”
Digital growth and customer loyalty are driven by how quickly organizations can determine and deliver the best experience for customers. However, existing solutions for A/B testing and feature flagging make it difficult to scale experimentation and rapid learning because they are disconnected from customer behavior. This gap means they lack both the analytics to design effective experiments and surface clear next steps and the behavioral data to target segments and manage user identity. The result is organizations get stuck in low-value activities that don’t drive growth - like testing small tweaks to copy and color changes or using basic on/off toggling to manage new feature release risk - or they waste resources and time on experiments that are doomed to fail - like starting from a weak hypothesis or not being able to reach the right segments.
Through the Behavioral Graph and Amplitude’s Digital Optimization System, Amplitude Experiment eliminates these challenges by resolving the underlying issues of experiment design, targeting, identity resolution and analysis. Now with the addition of the Amplitude Experiment solution, organizations have a complete learning and growth loop from insight to action to testing and delivery all within a single system.
- Amplitude Analytics identifies problems, uncovers opportunities, and measures impact.
- Amplitude Recommend matches the right messages, content, and items to each individual user.
- Amplitude Experiment tests bets and serves the best experience to customers.
“Our digital experience is core to the success of our business - the speed at which we experiment and test new features is critical. Amplitude Experiment is a game changer for Shift. Since it’s powered by customer behavior insights and analytics, we’re able to design better tests, learn from them faster and change the way we build and deliver experiences to our customers”, said Adam Johnston, Director of Product at Shift. “Amplitude has been a great partner to Shift on product analytics, and we are excited to have been able to deepen that relationship through the new Experiment product.”
Experiment is available now. To learn more please visit: amplitude.com/amplitude-experiment and to watch a short video visit: https://www.youtube.com/watch?v=eV4LAKXutqw
About Amplitude
Amplitude is the Digital Optimization System. Powered by the proprietary Amplitude Behavioral Graph, the Digital Optimization System enables organizations to see and predict which combination of features and actions translate to business outcomes — from loyalty to lifetime value — and intelligently adapt each experience in real time based on these insights. Amplitude is the brain behind more than 45,000 digital products at over 1,000 enterprise customers, including 23 of the Fortune 100, helping them innovate faster and smarter by answering the strategic question: “How do our digital products drive our business?” Learn more at https://amplitude.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005437/en/
Contact information
Kerry Rothery
Clarity PR for Amplitude
press@amplitude.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom